Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TKPHF) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to 14.17%.

  • Takeda Pharmaceutical's EBITDA Margin fell 38300.0% to 14.17% in Q4 2025 from the same period last year, while for Dec 2025 it was 26.74%, marking a year-over-year increase of 69500.0%. This contributed to the annual value of 7.48% for FY2025, which is 24600.0% up from last year.
  • Latest data reveals that Takeda Pharmaceutical reported EBITDA Margin of 14.17% as of Q4 2025, which was down 38300.0% from 28.52% recorded in Q3 2025.
  • Takeda Pharmaceutical's EBITDA Margin's 5-year high stood at 31.65% during Q1 2025, with a 5-year trough of 0.96% in Q1 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 16.96% (2023), whereas its average is 19.06%.
  • As far as peak fluctuations go, Takeda Pharmaceutical's EBITDA Margin tumbled by -168800bps in 2024, and later skyrocketed by 326100bps in 2025.
  • Over the past 5 years, Takeda Pharmaceutical's EBITDA Margin (Quarter) stood at 12.92% in 2021, then grew by 4bps to 13.4% in 2022, then surged by 66bps to 22.24% in 2023, then dropped by -19bps to 18.0% in 2024, then decreased by -21bps to 14.17% in 2025.
  • Its EBITDA Margin stands at 14.17% for Q4 2025, versus 28.52% for Q3 2025 and 28.72% for Q2 2025.